Parkinson’s disease (PD) is classically considered a motor disease; however, several non-motor symptoms are also present, including psychiatric complaints. In recent decades, the metals Ca, Fe, and Zn have gained prominence as potential etiologic factors in motoric signs of PD. However, metal alterations could be associated with the non-motor symptoms of PD. We wished to correlate the levels of these metals with the co-occurrence of depression, anxiety, and psychotic symptoms in PD patients. To this end, the Beck Depression Inventory, the Beck Anxiety Inventory, and the Scales for Outcomes in Parkinson’s disease-Psychiatric Complications (SCOPA-PC) were implemented to evaluate mood disorders and psychiatric complications. Flame atomic absorption spectrometry (FAAS) was used to assess concentrations of Ca, Fe, and Zn in hair samples collected from 22 clinically diagnosed PD patients, which represented the entire cohort of accessible patients in a Brazilian health registry, and 33 healthy individuals. While Ca and Fe alterations were not found to be associated with psychiatric complaints in the PD group, significantly higher levels of Zn were correlated in PD patients with depression and some psychotic symptoms. Within individual domains of the SCOPA-PC, significantly higher levels of Zn were correlated with the presence of hallucination, illusion, and paranoid ideation when compared to controls and PD patients who did not present these symptoms. Although our sample size is small and findings need to be replicated in larger and heterogeneous populations, our results provide a new perspective on the use of monitoring of Zn levels as a potential biomarker of psychiatric complaints, and may be useful in the development of more effective therapeutic approaches for the management of PD patients with co-occurrence of psychiatric disorders.
This is a preview of subscription content, access via your institution.
Buy single article
Instant access to the full article PDF.
Tax calculation will be finalised during checkout.
Subscribe to journal
Immediate online access to all issues from 2019. Subscription will auto renew annually.
Tax calculation will be finalised during checkout.
Aarsland D, Zaccai J, Brayne C (2005) A systematic review of prevalence studies of dementia in Parkinson’s disease. Mov Disord 20:1255–1263. https://doi.org/10.1002/mds.20527
Arnulf I, Leu S, Oudiette D (2008) Abnormal sleep and sleepiness in Parkinson’s disease. Curr Opin Neurol 24:472–477. https://doi.org/10.1097/WCO.0b013e328305044d
Barone P, Antonini A, Colosimo C et al (2009) The PRIAMO study: a multicenter assessment of nonmotor symptoms and their impact on quality of life in Parkinson’s disease. Mov Disord 24:1641–1649. https://doi.org/10.1002/mds.22643
Bengoa-Vergniory N, Roberts RF, Wade-Martins R, Alegre-Abarrategui J (2017) Alpha-synuclein oligomers: a new hope. Acta Neuropathol 134:819–838. https://doi.org/10.1007/s00401-017-1755-1
Bocca B, Alimonti A, Senofonte O et al (2006) Metal changes in CSF and peripheral compartments of parkinsonian patients. J Neurol Sci 248:23–30. https://doi.org/10.1016/j.jns.2006.05.007
Braak H, Del Tredici K, Rüb U et al (2003) Staging of brain pathology related to sporadic Parkinson’s disease. Neurobiol Aging 24:197–211. https://doi.org/10.1016/S0197-4580(02)00065-9
Cunha JA (2001) Manual da versão em português das Escalas Beck. Casa do Psicólogo, São Paulo. On-line version ISSN 2175-3563. https://doi.org/10.1590/s1413-82712007000100004
de Bartolomeis A, Latte G, Tomasetti C, Iasevoli F (2014) Glutamatergic postsynaptic density protein dysfunctions in synaptic plasticity and dendritic spines morphology: relevance to schizophrenia and other behavioral disorders pathophysiology, and implications for novel therapeutic approaches. Mol Neurobiol 49:484–511. https://doi.org/10.1007/s12035-013-8534-3
dos Santos AB, Kohlmeier KA, Rocha ME et al (2018) Hair in Parkinson’s disease patients exhibits differences in calcium, iron and zinc concentrations measured by flame atomic absorption spectrometry (FAAS). J Trace Elem Med Biol 47:134–139. https://doi.org/10.1016/j.jtemb.2018.02.003
Fénelon G (2000) Hallucinations in Parkinson’s disease: prevalence, phenomenology and risk factors. Brain 123:733–745. https://doi.org/10.1093/brain/123.4.733
Fénelon G (2008) Psychosis in Parkinson’s disease: phenomenology, frequency, risk factors, and current understanding of pathophysiologic mechanisms. CNS Spectr 13:18–25. https://doi.org/10.1017/S1092852900017284
Fénelon G, Alves G (2010) Epidemiology of psychosis in Parkinson’s disease. J Neurol Sci. https://doi.org/10.1016/j.jns.2009.08.014
Ffytche DH, Creese B, Politis M et al (2017) The psychosis spectrum in Parkinson’s disease. Nat Rev Neurol 13:81–95. https://doi.org/10.1038/nrneurol.2016.200
Fink AL (2006) The aggregation and fibrillation of α-synuclein. Acc Chem Res 39:628–634. https://doi.org/10.1021/ar050073t
Forte G, Alimonti A, Violante N et al (2005) Calcium, copper, iron, magnesium, silicon and zinc content of hair in Parkinson’s disease. J Trace Elem Med Biol 19:195–201. https://doi.org/10.1016/j.jtemb.2005.08.003
Fukushima T, Tan X, Luo Y et al (2013) Heavy metals in blood and urine and its relation to depressive symptoms in Parkinson’s disease patients. Fukushima J Med Sci 59:76–80. https://doi.org/10.5387/fms.2014-8
Gammoh NZ, Rink L (2017) Zinc in infection and inflammation. Nutrients 9(6):624. https://doi.org/10.3390/nu9060624
Gibson G, Mottram PG, Burn DJ et al (2013) Frequency, prevalence, incidence and risk factors associated with visual hallucinations in a sample of patients with Parkinson’s disease: a longitudinal 4-year study. Int J Geriatr Psychiatry 28(6):626–631. https://doi.org/10.1002/gps.3869
Harding AJ, Stimson E, Henderson JM, Halliday GM (2002) Clinical correlates of selective pathology in the amygdala of patients with Parkinson’s disease. Brain 125(Pt 11):2431–2445. https://doi.org/10.1093/brain/awf251
Iasevoli F, Tomasetti C, Buonaguro EF, de Bartolomeis A (2014) The glutamatergic aspects of schizophrenia molecular pathophysiology: role of the postsynaptic density, and implications for treatment. Curr Neuropharmacol 12:219–238. https://doi.org/10.2174/1570159X12666140324183406
Jaishankar M, Tseten T, Anbalagan N et al (2014) Toxicity, mechanism and health effects of some heavy metals. Interdiscip Toxicol 7:60–72. https://doi.org/10.2478/intox-2014-0009
Janzen J, Van’T Ent D, Lemstra AW et al (2012) The pedunculopontine nucleus is related to visual hallucinations in Parkinson’s disease: preliminary results of a voxel-based morphometry study. J Neurol 259(1):147–154. https://doi.org/10.1007/s00415-011-6149-z
Jiao J, Guo H, He Y et al (2016) Meta-analysis of the association between serum iron levels and Parkinson’s disease: evidence from 11 publications. Brain Res 1646:490–493. https://doi.org/10.1016/j.brainres.2016.06.044
Lai J, Moxey A, Nowak G et al (2012) The efficacy of zinc supplementation in depression: systematic review of randomised controlled trials. J Affect Disord 136(1–2):e31–e39. https://doi.org/10.1016/jAD.2011.06.022
Lauterbach EC (2004) Differential DSM-III psychiatric disorder prevalence profiles in dystonia and Parkinson’s disease. J Neuropsychiatr 16:29–36. https://doi.org/10.1176/appi.neuropsych.16.1.29
Leal SS, Botelho HM, Gomes CM (2012) Metal ions as modulators of protein conformation and misfolding in neurodegeneration. Coord Chem Rev 256:2253. https://doi.org/10.1016/j.ccr.2012.04.004
Marsh L (2013) Depression and Parkinson’s disease: current knowledge. Curr Neurol Neurosci Rep 1:2. https://doi.org/10.1007/s11910-013-0409-5
Miyake Y, Tanaka K, Fukushima W et al (2011) Dietary intake of metals and risk of Parkinson’s disease: a case-control study in Japan. J Neurol Sci 306:98–102. https://doi.org/10.1016/j.jns.2011.03.035
Miyasaki JM, Al Hassan K, Lang AE, Voon V (2007) Punding prevalence in Parkinson’s disease. Mov Disord 22(8):1179–1181. https://doi.org/10.1002/mds.21296
Mlyniec K (2015) Zinc in the glutamatergic theory of depression. Curr Neuropharmacol 13(4):505–513. https://doi.org/10.2174/1570159X13666150115220617
Młyniec K, Davies CL, de Agüero Sánchez IG et al (2014) Essential elements in depression and anxiety. Part I. Pharmacol Rep 66:534–544. https://doi.org/10.1016/j.pharep.2014.03.001
Mostile G, Cicero CE, Giuliano L et al (2017) Iron and Parkinson’s disease: a systematic review and meta-analysis. Mol Med Rep 15(5):3383–3389. https://doi.org/10.3892/mmr.2017.6386
Petrilli MA, Kranz TM, Kleinhaus K et al (2017) The emerging role for zinc in depression and psychosis. Front Pharmacol 8:414. https://doi.org/10.3389/fphar.2017.00414
Ranjbar E, Shams J, Sabetkasaei M et al (2014) Effects of zinc supplementation on efficacy of antidepressant therapy, inflammatory cytokines, and brain-derived neurotrophic factor in patients with major depression. Nutr Neurosci 17:65–71. https://doi.org/10.1179/1476830513Y.0000000066
Reijnders JS, Ehrt U, Weber WE et al (2008) A systematic review of prevalence studies of depression in Parkinson’s disease. Mov Disord 23:183–189. https://doi.org/10.1002/mds.21803
Romana Pezzella F, Colosimo C, Vanacore N et al (2005) Prevalence and clinical features of hedonistic homeostatic dysregulation in Parkinson’s disease. Mov Disord 20:77–81. https://doi.org/10.1002/mds.20288
Schwartz TL, Sachdeva S, Stahl SM (2012) Glutamate neurocircuitry: theoretical underpinnings in schizophrenia. Front Pharmacol 3:195. https://doi.org/10.3389/fphar.2012.00195
Solati Z, Jazayeri S, Tehrani-Doost M et al (2015) Zinc monotherapy increases serum brain-derived neurotrophic factor (BDNF) levels and decreases depressive symptoms in overweight or obese subjects: a double-blind, randomized, placebo-controlled trial. Nutr Neurosci 18:162–168. https://doi.org/10.1179/1476830513Y.0000000105
Stelmashook EV, Isaev NK, Genrikhs EE et al (2014) Role of zinc and copper ions in the pathogenetic mechanisms of Alzheimer’s and Parkinson’s diseases. Biochemistry 79:391–396. https://doi.org/10.1134/S0006297914050022
Surmeier DJ, Schumacker PT, Guzman JD et al (2017) Calcium and Parkinson’s disease. Biochem Biophys Res Commun 483(4):1013–1019. https://doi.org/10.1016/j.bbrc.2016.08.168
Swardfager W, Herrmann N, Mazereeuw G et al (2013) Zinc in depression: a meta-analysis. Biol Psychiatry 74:872–878. https://doi.org/10.1016/j.biopsych.2013.05.008
Swardfager W, Herrmann N, Mazereeuw G, Lanctôt KL (2015) Reply to: serum zinc and the risk of depression in men: observations from a 20-year follow-up study. Biol Psychiatry 77:e13–e14. https://doi.org/10.1016/j.biopsych.2014.06.006
Szewczyk B, Poleszak E, Sowa-Kućma M et al (2010) The involvement of NMDA and AMPA receptors in the mechanism of antidepressant-like action of zinc in the forced swim test. Amino Acids 39:205–217. https://doi.org/10.1007/s00726-009-0412-y
Tsai G, Lin P-Y (2010) Strategies to enhance N-methyl-D-aspartate receptor-mediated neurotransmission in schizophrenia, a critical review and meta-analysis. Curr Pharm Des 16:522–537. https://doi.org/10.2174/138161210790361452
Uversky VN, Li J, Fink AL (2001) Metal-triggered structural transformations, aggregation, and fibrillation of human alpha-synuclein. A possible molecular link between Parkinson’s disease and heavy metal exposure. J Biol Chem 276:44284–44296. https://doi.org/10.1074/jbc.M105343200
Vashum KP, McEvoy M, Milton AH et al (2014) Dietary zinc is associated with a lower incidence of depression: findings from two Australian cohorts. J Affect Disord 166:249–257. https://doi.org/10.1016/j.jad.2014.05.016
Visser M, Verbaan D, van Rooden SM et al (2007) Assessment of psychiatric complications in Parkinson’s disease: the SCOPA-PC. Mov Disord 22:2221–2228. https://doi.org/10.1002/mds.21696
Wang Y, Shi M, Chung KA et al (2012) Phosphorylated α-synuclein in Parkinson’s disease. Sci Trans Med 4:121ra20. https://doi.org/10.1126/scitranslmed.3002566
Willams DR, Warren JD, Lees AJ (2008) Using the presence of visual hallucinations to differentiate Parkinson’s disease from atypical parkinsonism. J Neurol Neurosurg Psychiatry 1:2. https://doi.org/10.1136/jnnp.2007.124677
Yu X, Du T, Song N et al (2013) Decreased iron levels in the temporal cortex in postmortem human brains with Parkinson’s disease. Neurology 80:492–495. https://doi.org/10.1212/WNL.0b013e31827f0ebb
Zhang G, Zhang G et al (2014) Impulisve and compulsive behaviors in Parkinson’s disease. Front Aging Neurosci 6:318. https://doi.org/10.3389/fnag
Zhao H-W, Lin J, Wang X-B et al (2013) Assessing plasma levels of selenium, copper, iron and zinc in patients of Parkinson’s disease. PLoS One 8:e83060. https://doi.org/10.1371/journal.pone.0083060
Coordenação de Aperfeiçoamento de Pessoal de Nível Superior (CAPES), Brazil for funding support of a Ph.D Grant to Altair Brito dos Santos.
This work was financially supported by Coordenação de Aperfeiçoamento de Pessoal de Nível Superior (CAPES), Brazil. Grant Numbers (99999.012934/2013-05).
Conflict of interest
The authors declare that they have no conflict interests.
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
We are the first to show that Zn alterations in PD patients are associated with psychiatric symptoms frequently seen in this disease and the first to provide an easy clinical chemistry assay combining hair samples and FAAS to evaluate Zn levels in PD patients and to correlate levels with mild psychiatric disorders.
About this article
Cite this article
Dos Santos, A.B., Bezerra, M.A., Rocha, M.E. et al. Higher zinc concentrations in hair of Parkinson’s disease are associated with psychotic complications and depression. J Neural Transm 126, 1291–1301 (2019). https://doi.org/10.1007/s00702-019-02041-9
- Metal imbalance
- Non-motor symptoms